Industrials

CUV are conducting two Phase 3 trials to expand the label of Scenesse to include patients with vitiligo.

The Canadian Government has announced several material policy changes targeting international students, however these changes on IDP are unclear.

IPD has announced the acquisition of CMI Operations for an upfront $92.1m and contingent consideration of up to $8.9m. Our revised PT is $5.75 (prev. $5.50) with our Buy recommendation remaining unchanged.

We have updated each valuation for IPD Education used in the determination of our PT for the forecast changes and recent market movements. We upgrade to a Buy recommendation and a price target of $27.00.

TSK reported a 2Q24 update outlining continued strong momentum regarding client wins, deployments and cash flows. We maintain our Buy recommendation and reduce our Price Target to $0.57/sh (previously $0.62/sh).